News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
The first non-profit 100% dedicated to Myelodysplastic Syndromes – MDS Foundation
Jan 6, 2025, 12:28

The first non-profit 100% dedicated to Myelodysplastic Syndromes – MDS Foundation

MDS Foundation shared a post on X:

“At The MDS Foundation, we are proud to be the first non-profit 100% dedicated to Myelodysplastic Syndromes (MDS).

We bring together dedicated experts, caregivers, and patients, harnessing their energy, passion, and optimism to make meaningful progress against MDS.

Together, we say no to the incurable and work tirelessly to create solutions.

We’re here to support, educate, and empower the MDS community. Learn more about our mission at MDS-Foundation.org.”

cancer MDS Foundation myelodysplastic syndromes OncoDaily Oncology
Special Coverage
Insight
Jun 1, 2025, 14:50
Pashtoon Kasi Highlighted Study on Vilastobart (XTX101) + Atezolizumab in MSS Colorectal Cancer at ASCO 2025
Science
Jun 1, 2025, 14:48
First results of SURE-02 Trial presented at ASCO 2025 by Andrea Necchi
Insight
Jun 1, 2025, 14:41
Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025
Blog
Jun 1, 2025, 14:39
Christina Ip-Toma: Integrating germline and tumor genetic results to reduce disparities in cancer care
Blog
Jun 1, 2025, 14:38
Key Insights by Petros Grivas from ASCO25
Science
Jun 1, 2025, 14:38
Kriti Mittal: The ASCO special edition of the ASPIRE CoP newsletter
Oncolibrary
Jun 1, 2025, 13:48
Romiplostim for Chemotherapy-induced Thrombocytopenia Results from global phase iii trial in Gi cancers
Opinion
Jun 1, 2025, 13:42
Efficacy of IL-6R Blockade with Sarilumab in a Quadruple Immuno-Oncology Regimen for Patients with Unresectable Stage III/IV Melanoma
Oncolibrary
Jun 1, 2025, 13:02
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus Ipilimumab Continues to Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Oncolibrary
Jun 1, 2025, 12:40
Metacure Cohorts B2 Results: Intensified Hormonal Blockade and SBRT for PSMA-PET Detected Oligometastatic Prostate Adenocarcinoma
Oncolibrary
Jun 1, 2025, 12:03
EV-302 Updates at ASCO 2025: Enfortumab Vedotin Plus Pembrolizumab Doubles Complete Response Rate in Advanced Urothelial Carcinoma
Oncolibrary
Jun 1, 2025, 11:55
Tagitanlimab Boosts Chemotherapy in Nasopharyngeal Cancer: Phase 3 Results at ASCO 2025